Carole Ho, MD

Carole Ho is the Chief Medical Officer and Head of Development at Denali Therapeutics where she leads an integrated organization responsible for advancing programs from preclinical development through global Phase 3 trials. Since joining Denali in 2015, she has overseen the advancement of multiple therapeutic candidates in rare and neurodegenerative diseases including Lysosomal Storage Disease, Parkinson’s disease, Alzheimer’s disease, ALS, and FTD. Prior to Denali, Dr. Ho was Vice President of Clinical Development at Genentech, where she led programs in neurology, immunology, ophthalmology, and infectious disease. Her work contributed to the development of pivotal therapies including Ocrelizumab for multiple sclerosis and Rituxan for autoimmune conditions. She also initiated the first-ever Alzheimer’s disease prevention trial in genetically at-risk individuals in Colombia, in collaboration with Banner Health. Dr. Ho began her career in academic medicine at Stanford University. She earned her MD from Cornell University and completed her neurology residency and Chief Residency at Harvard Medical School/MGH/Brigham and Women’s Hospital. She holds a degree in biochemical sciences from Harvard College and currently serves on the Board of Directors of Beam Therapeutics and previously served on the Board of Directors of NGM Bio.